Pivagabine

DB12951

small molecule investigational

Deskripsi

Pivagabine has been used in trials studying the treatment of Stress and Anxiety.

Struktur Molekul 2D

Berat 187.239
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

676 Data
Buprenorphine Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Hydrocodone Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Magnesium sulfate The therapeutic efficacy of Pivagabine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Pivagabine may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Mirtazapine Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Orphenadrine Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Pramipexole Pivagabine may increase the sedative activities of Pramipexole.
Ropinirole Pivagabine may increase the sedative activities of Ropinirole.
Rotigotine Pivagabine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Pivagabine.
Sodium oxybate Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Thalidomide Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Pivagabine.
Dicoumarol The risk or severity of adverse effects can be increased when Pivagabine is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Pivagabine is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Pivagabine is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Pivagabine is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Pivagabine is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Pivagabine is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Pivagabine is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Pivagabine is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Pivagabine is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Pivagabine is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Pivagabine is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Pivagabine is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Pivagabine is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Pivagabine is combined with (S)-Warfarin.
Ethanol Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Pivagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Fluvoxamine The risk or severity of adverse effects can be increased when Pivagabine is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Pivagabine is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Pivagabine is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Pivagabine is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Pivagabine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Pivagabine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Pivagabine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Pivagabine is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Pivagabine is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Pivagabine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Pivagabine is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Pivagabine is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Pivagabine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Pivagabine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Pivagabine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Pivagabine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Pivagabine is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Pivagabine is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Pivagabine.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Pivagabine.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Pivagabine.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Pivagabine.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Pivagabine.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Pivagabine.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Pivagabine.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Pivagabine.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Pivagabine.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Pivagabine.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Pivagabine.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Pivagabine.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Pivagabine.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Pivagabine.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Pivagabine.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Pivagabine.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Pivagabine.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Pivagabine.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Pivagabine.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Pivagabine.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Pivagabine.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Pivagabine.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Pivagabine.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Pivagabine.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Pivagabine.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Pivagabine.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Pivagabine.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Pivagabine.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Pivagabine.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Pivagabine.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Pivagabine.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Pivagabine.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Pivagabine.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Pivagabine.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Pivagabine.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Pivagabine.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Pivagabine.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Pivagabine.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Pivagabine.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Pivagabine.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Tonerg

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul